Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib Study of RSV Vaccine LID/ΔM2-2/1030s in Infants and Children
NCT04520659Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2022
- Primary completion
- Apr 2024
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised trial of RSV LID ΔM2-2 1030s in respiratory syncytial virus infection (RSV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Frequency of Grade 1 or Higher Solicited Adverse Events (AEs) by Grade at Day 28, Frequency of Grade 2 or Higher Lower Respiratory Infections (LRI) by Grade at Day 28 and 5 more. Started Mar 2022; status: completed.
02
Drugs
RSV LID ΔM2-2 1030s
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04520659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04520659.